产碳青霉烯酶与非产碳青霉烯酶碳青霉烯耐药肠杆菌血流感染结局比较
一项观察性研究比较产碳青霉烯酶(CP)与非产碳青霉烯酶(non-CP)碳青霉烯耐药肠杆菌(CRE)血流感染患者的14天死亡率。共83例单一菌种CRE血流感染,CP-CRE组37例(45%),non-CP-CRE组46例(55%)。调整疾病严重度、基础疾病和抗生素治疗后,CP-CRE组14天死亡风险显著高于non-CP-CRE组(调整OR 4.92,95%CI 1.01-24.81)。
要点
- CP-CRE血流感染14天死亡率32%,non-CP-CRE为13%。
- 调整混杂后CP-CRE死亡风险为non-CP-CRE的4.92倍(95%CI 1.01-24.81)。
- CP-CRE以blaKPC为主(92%),美罗培南MIC多≥16 µg/mL。
核心结论
- CP-CRE血流感染可能比non-CP-CRE更具毒力,且与更差结局相关。
- 明确CRE耐药机制对指导抗生素治疗决策具有额外重要性。
研究设计与样本
- 观察性研究,比较CP-CRE与non-CP-CRE血流感染患者的14天死亡率。
- 共纳入83例单一菌种CRE血流感染,CP-CRE 37例(45%),non-CP-CRE 46例(55%)。
- 对所有分离株进行基于DNA微阵列的检测以鉴定β-内酰胺酶编码基因。
主要发现
- CP-CRE分离株中blaKPC占92%,blaNDM占5%,blaOXA-48型占3%。
- 14天内共18例(22%)死亡,CP-CRE组12例(32%),non-CP-CRE组6例(13%)。
- 调整第1天疾病严重度、基础疾病和抗生素治疗差异后,CP-CRE组14天死亡调整OR为4.92(95%CI 1.01-24.81)。
临床怎么用
- 对CRE血流感染分离株应明确碳青霉烯酶产生状态及耐药机制,以辅助预后判断和抗生素选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) are associated with considerable mortality. As mechanisms of carbapenem resistance are heterogeneous, it is unclear if mortality differs based on resistance mechanisms. We sought to determine whether CRE resistance mechanism determination is prognostically informative. METHODS: We conducted an observational study comparing 14-day mortality between patients with carbapenemase-producing (CP)-CRE compared with non-CP-CRE bacteremia. Clinical data were collected on all patients. A comprehensive DNA microarray-based assay was performed on all isolates to identify β-lactamase-encoding genes. RESULTS: There were 83 unique episodes of monomicrobial CRE bacteremia during the study period: 37 (45%) CP-CRE and 46 (55%) non-CP-CRE. The majority of CP-CRE isolates were bla KPC (92%), followed by bla NDM (5%) and bla OXA-48-type (3%). CP-CRE isolates were more likely to have meropenem minimum inhibitory concentrations (MICs) ≥16 µg/mL, while non-CP-CRE isolates were more likely to have meropenem MICs ≤1 µg/mL (P value < .001). A total of 18 (22%) patients died within 14 days, including 12 (32%) in the CP-CRE group and 6 (13%) in the non-CP-CRE group. Adjusting for severity of illness on day 1 of bacteremia, underlying medical conditions, and differences in antibiotic treatment administered, the odds of dying within 14 days were more than 4 times greater for CP-CRE compared with non-CP-CRE bacteremic patients (adjusted odds ratio, 4.92; 95% confidence interval, 1.01-24.81). CONCLUSION: Our findings suggest that CP-CRE may be more virulent than non-CP-CRE and are associated with poorer outcomes. This underscores the added importance of delineating underlying resistance mechanisms of CRE to direct antibiotic treatment decisions.
引用
- Tamma PD, Goodman KE, Harris AD, et al. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis. 2016. PMID: 28013264. doi:10.1093/cid/ciw741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。